Clinical Trials Logo

Clinical Trial Summary

Patients at high risk of IVIG-associated hemolysis (defined as receipt of a 28-day cumulative dose of ≥ 2 g/kg, adjusted for ideal body weight, and non-O blood group) will be prospectively monitored using a standardized protocol for signs of hemolysis, and will be undergo additional testing for variables that have been hypothesized to increase the risk of hemolysis. The goal of the study is to define the incidence and dynamics of IVIG-mediated hemolysis and identify patient and product-related factors that may predict which patients are especially at risk.


Clinical Trial Description

All IVIG orders received by the blood transfusion service at participating sites will be screened for patient eligibility. All non-O blood group patients receiving a cumulative 28-day dose of IVIG ≥ 2 g/kg will be approached for enrolment. Exclusion criteria include the presence of an alternate cause of anemia, including blood loss, other drug-induced hemolysis, anemia associated with chemotherapy for cancer, or hemolysis associated with an underlying disease or participation in another ongoing study. Patients receiving repeated courses of therapy will be eligible for re-enrollment a maximum of 6 times. There are otherwise no exclusions on the basis of age, diagnosis, concurrent treatment, or specific brand of product received. Enrolment will occur at multiple Canadian health care facilities.

Upon enrolment,case report forms documenting the participant's previous medical history, IVIG treatments and adverse reactions, and concurrent medication use will be collected. Laboratory testing for hemolysis will be performed at baseline, immediately following the completed high-dose cycle (usually administered over 1-2 days), and then again at 5-10 days post-infusion. IVIG associated. Hemolysis will be defined and graded as per the criteria of the Canadian IVIG Pharmacovigilance Group. The pathophysiology of IVIG-associated hemolysis will be characterized by tracking changes in serum complement levels, performing extended cytokine profiling, and conducting mononuclear phagocyte activity assays using patient monocytes. Secretor gene status, ABO zygosity and FcR polymorphisms will also be determined. A predictive model incorporating both patient factors (eg., blood group, total dose prescribed, presence of pre-infusion inflammation) and product factors (eg., specific lot number) will then be developed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02259478
Study type Observational
Source Toronto Transfusion Medicine Collaborative
Contact
Status Completed
Phase N/A
Start date October 2014
Completion date December 2016

See also
  Status Clinical Trial Phase
Completed NCT03439605 - Effect of in Vitro Haemolysis on Serum High Sensitivity Troponin T Measurements From Patients in Accident & Emergency N/A
Completed NCT03434145 - Changes of Ocular Structures After Hemodialysis in Patients With Chronic Kidney Diseases N/A
Completed NCT04084301 - Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury N/A
Not yet recruiting NCT01201174 - Hemolysis in Patients With Hereditary Spherocytosis (HS) N/A
Completed NCT03582592 - Fluid Distribution Timetable on Adherence to Fluid Restriction of Patients With End-Stage Renal Disease on Hemodialysis N/A
Not yet recruiting NCT05754294 - Electric Polarization of Red Blood Cells : A Cohort Study to Assess the Erythrocytes Membrane Integrity Through Charge Conservation, Following Cardiac Surgery.
Completed NCT02996786 - Effects of Danggui Buxue Tang on Blood Biochemical Parameters in Male Recreational Runners N/A
Not yet recruiting NCT05647200 - Optimization of Prime Fluid Strategy to Preserve Microcirculatory Perfusion During Cardiac Surgery With Cardiopulmonary Bypass, Part II N/A
Completed NCT05962268 - The Effect Of Vıdeo-Based Fıstula Care Educatıon On Hemodıalysıs N/A
Recruiting NCT06223802 - Biodex Training in Hemodialysis Females With Osteopenia N/A
Active, not recruiting NCT00792779 - Protective Effect of Propofol Against Hemolysis in Patients Submitted to Gastroplasty N/A
Not yet recruiting NCT06096428 - Hemolysis During Pulsed-field and Radiofrequency Ablation
Recruiting NCT03330223 - Effect of Haemodialysis on the Efficacy of Antiplatelet Agents N/A
Completed NCT04203784 - Meropenem and Piperacillin Plasma Concentrations During CRRT
Completed NCT06215339 - Diet Therapy in Hemodialysis Patients N/A
Recruiting NCT05539248 - A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH Phase 1/Phase 2
Recruiting NCT03633435 - Home Hemodialysis Assisted by a Nurse for Arterio-venous Fistula Cannulation N/A
Withdrawn NCT02217683 - Use of Inhaled Nitric Oxide to Prevent Pulmonary Hypertension Associated to Stored Blood Transfusion Phase 2
Completed NCT03199612 - Sildenafil To Prevent Clot Early Phase 1
Completed NCT02711332 - Investigating the Influence of Haemolysis on the Potassium Concentration After Capillary Blood Sampling N/A